Published in J Hematol Oncol on July 02, 2012
Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int (2013) 0.89
Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Exp Hematol Oncol (2014) 0.83
Impact of Epigenetic Dietary Components on Cancer through Histone Modifications. Curr Med Chem (2015) 0.82
Mechanism of G9a inhibitor BIX‑01294 acting on U251 glioma cells. Mol Med Rep (2016) 0.75
Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL-60 cells. Oncol Lett (2017) 0.75
Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells. Int J Mol Med (2017) 0.75
Translating the histone code. Science (2001) 56.77
The language of covalent histone modifications. Nature (2000) 44.92
Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell (2001) 11.39
Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev (2001) 9.54
SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev (2002) 8.78
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem (2001) 7.21
JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet (2006) 6.65
The many faces of histone lysine methylation. Curr Opin Cell Biol (2002) 6.01
Histones and histone modifications. Curr Biol (2004) 5.78
Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell (2004) 4.99
5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene (2002) 4.81
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol (2004) 4.72
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nat Genet (2001) 3.63
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene (2002) 2.97
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci (2002) 2.80
The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci U S A (1998) 2.52
Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer (2004) 2.00
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 1.92
Histone H3 lysine 4 methylation is mediated by Set1 and promotes maintenance of active chromatin states in fission yeast. Proc Natl Acad Sci U S A (2002) 1.87
Mechanisms of transformation by MLL. Crit Rev Eukaryot Gene Expr (2004) 1.70
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol (2011) 1.31
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol (2010) 1.18
Relationship between methylation and acetylation of arginine-rich histones in cycling and arrested HeLa cells. Biochemistry (1995) 1.16
Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol (2006) 1.11
Distribution of methylated histones and histone methyltransferases in chicken erythrocyte chromatin. J Biol Chem (1989) 1.08
Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol (2012) 1.06
Targeted therapy in lymphoma. J Hematol Oncol (2010) 1.05
Histone methyltransferases: regulation of transcription and contribution to human disease. J Mol Med (Berl) (2010) 0.89
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep (2006) 0.84
Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol (2009) 0.79
[Experiment study of PHI on histone methylation and acetylation in Molt-4 cells]. Zhonghua Xue Ye Xue Za Zhi (2007) 0.79
[Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in Molt-4 cells]. Yao Xue Xue Bao (2009) 0.77
Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis. Acta Trop (2009) 1.15
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol (2011) 0.99
Evaluation of the quality of deep frying oils with Fourier transform near-infrared and mid-infrared spectroscopy. J Food Sci (2012) 0.96
Energy-dependent electron activated dissociation of metal-adducted permethylated oligosaccharides. Anal Chem (2012) 0.96
Discrimination of intact and injured Listeria monocytogenes by Fourier transform infrared spectroscopy and principal component analysis. J Agric Food Chem (2004) 0.95
Analyses of enrofloxacin, furazolidone and malachite green in fish products with surface-enhanced Raman spectroscopy. Food Chem (2012) 0.91
Detailed glycan structural characterization by electronic excitation dissociation. Anal Chem (2013) 0.87
Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res (2006) 0.84
The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep (2006) 0.84
Rapid determination of ractopamine in swine urine using surface-enhanced Raman spectroscopy. J Agric Food Chem (2011) 0.82
Structural heterogeneity of doubly-charged peptide b-ions. J Am Soc Mass Spectrom (2011) 0.82
Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol (2009) 0.79
Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol (2010) 0.79
Rapid discrimination of Alicyclobacillus strains in apple juice by Fourier transform infrared spectroscopy. Int J Food Microbiol (2005) 0.77
[Effect of siRNA targeting HDAC1 gene on proliferation, apoptosis, histone acetylation, and histone methylation in gastric cancer cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao (2014) 0.77
[Effect of phenelzine on the proliferation, apoptosis and histone methylation and acetylation of Molt-4 cells]. Zhonghua Xue Ye Xue Za Zhi (2016) 0.75
Bruise detection in Pacific pink salmon (Oncorhynchus gorbuscha) by visible and short-wavelength near-infrared (SW-NIR) spectroscopy (600-1100 nm). J Agric Food Chem (2003) 0.75
Determination of tert-butylhydroquinone in vegetable oils using surface-enhanced Raman spectroscopy. J Food Sci (2014) 0.75
[Antiproliferative effect of silencing LSD1 gene on Jurkat cell line and its mechanism]. Zhonghua Xue Ye Xue Za Zhi (2016) 0.75
[Key points of quality control of critical care medicine under the new situation]. Zhonghua Yi Xue Za Zhi (2014) 0.75